leadf
logo-loader
viewOncimmune

Oncimmune does deals to develop cancer tests

Group says deals will allow it to develop tests to distinguish between malignant and benign cancer

shutterstock_306682595.jpg
Oncimmune has developed tests able to detect cancer up to four years earlier than other methods

Oncimmune Holdings plc (LON:ONC) has done deals with a research company and a Danish university to help it develop its cancer diagnosis technology.

The company said Egybiotech and Aarhus University Hospital would provide blood samples and clinical data to develop tests able to distinguish between malignant and benign liver and ovarian cancers.

Oncimmune has developed autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a wide range of solid tumour types.

It said the tie-ups with Egybiotech and the university would keep it on track to launch the tests commercially in 2017.

Chief executive Geoffrey Hamilton-Fairley said: "Current biomarkers for liver and ovarian cancer perform poorly and our EarlyCDT technology has the potential to allow earlier diagnosis of these serious diseases."

 

 

Quick facts: Oncimmune

Price: 142.5 GBX

AIM:ONC
Market: AIM
Market Cap: £90.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read